Highbridge Capital Management
HCM is a global alternative investment management firm launched in 1992. Since its inception, the company has developed a diversified
Business Model:
Revenue: $35M
Employees: 201-500
Rankings
Industries / Tags:
Detailed Highbridge Capital Management Information
Geographic Data
Address: 277 Park Avenue
City: New York
State: NY
Zip: 10172
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Facebook
Linkedin
Crunchbase
Metrics
3,856,296Website Global Rank
3,255Website Monthly Traffic
Twitter Followers
Description
HCM is a global alternative investment management firm launched in 1992. Since its inception, the company has developed a diversified investment platform that includes hedge funds, traditional investment management products and debt and private equity investments with longer-term holding periods. With over 300 employees, including almost 100 investment professionals, HCM manages approximately $21 billion of capital for some of the world&s;s most prominent institutional investors, public and corporate pension funds, endowments, foundations and family offices.
Contact Phone:
+12122872500
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2021 | Lime | Convertible Note | 0 |
| 12/2005 | EUSA Pharma | Venture Round | 0 |
| 6/2020 | Santhera Pharmaceuticals | Post-IPO Debt | 0 |
| 8/2017 | Inseego | Post-IPO Debt | 48M |
| 9/2021 | Santhera Pharmaceuticals | Post-IPO Debt | 0 |
| 9/2021 | Santhera Pharmaceuticals | Post-IPO Equity | 0 |
| 10/2022 | Invacare | Post-IPO Debt | 18.5M |
| 3/2005 | Lexar | Private Equity Round | 60M |
| 5/2000 | Strategic Data Corp | Series B | 0 |
| 12/2021 | CompoSecure | Post-IPO Equity | 175M |
| 12/2022 | Invacare | Post-IPO Debt | 5.5M |
| 8/2005 | BravoSolution | Venture Round | 0 |
| 12/2021 | Urgently | Debt Financing | 0 |
| 7/2005 | Pharmacopeia | Venture Round | 0 |
| 3/2020 | Protalix BioTherapeutics | Post-IPO Equity | 0 |
| 9/2022 | Gamida Cell | Post-IPO Debt | 25M |
| 12/2021 | BigBear.ai | Post-IPO Debt | 0 |
| 11/2006 | EUSA Pharma | Venture Round | 0 |
| 7/2013 | Emergent Payments | Series C | 0 |
| 5/2021 | Quotient Biodiagnostics | Post-IPO Debt | 0 |
| 1/2007 | ACE*COMM | Private Equity Round | 0 |
| 2/2021 | Gamida Cell | Debt | 75M |
| 3/2022 | Starry | Post-IPO Debt | 0 |
| 12/2021 | CompoSecure | Post-IPO Equity | 0 |
| 12/2021 | Urgently | Debt Financing | 0 |
| 12/2021 | BigBear.ai | Post-IPO Debt | 0 |
| 11/2021 | Lime | Convertible Note | 0 |
| 9/2021 | Santhera Pharmaceuticals | Post-IPO Equity | 0 |
| 9/2021 | Santhera Pharmaceuticals | Post-IPO Debt | 0 |
| 5/2021 | Quotient Biodiagnostics | Post-IPO Debt | 0 |
| 2/2021 | Gamida Cell | Post-IPO Debt | 0 |
| 6/2020 | Santhera Pharmaceuticals | Post-IPO Debt | 0 |
| 3/2020 | Protalix BioTherapeutics | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
